يعرض 1 - 20 نتائج من 169 نتيجة بحث عن '"Knyazeva, I. A."', وقت الاستعلام: 0.67s تنقيح النتائج
  1. 1
    Report
  2. 2
    Academic Journal

    المصدر: Geomagnetism & Aeronomy; Dec2024, Vol. 64 Issue 7, p1157-1162, 6p

  3. 3
    Academic Journal

    المصدر: Сборник статей

    وصف الملف: application/pdf

    Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; Гендерные и возрастные особенности нарушений сна у пациентов с первичными головными болями / Е. А. Тверитин, Я. А. Князева, Е. А. Сизикова [и др.]. - Текст электронный. // Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г. – Екатеринбург : УГМУ, 2023. – C. 2086-2091.; http://elib.usma.ru/handle/usma/14293

  4. 4
    Conference

    المصدر: AIP Conference Proceedings ; PROCEEDINGS OF THE 2ND INTERNATIONAL INTERDISCIPLINARY SCIENTIFIC CONFERENCE “DIGITALIZATION AND SUSTAINABILITY FOR DEVELOPMENT MANAGEMENT: ECONOMIC, SOCIAL, AND ENVIRONMENTAL ASPECTS” ; volume 3033, page 060015 ; ISSN 0094-243X

  5. 5
    Academic Journal

    Relation: The effect of amber acid on the productivity and chemical composition of tomatoes grown in a climatic chamber / I.V. Knyazeva [et al.] // Scientific Study and Research - Chemistry and Chemical Engineering, Biotechnology, Food Industry. - 2021. - Vol.22, №3.-P. 311-319.; http://dspace.bsu.edu.ru/handle/123456789/51499

  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal

    المصدر: Rheumatology Science and Practice; Vol 57, No 3 (2019); 312-317 ; Научно-практическая ревматология; Vol 57, No 3 (2019); 312-317 ; 1995-4492 ; 1995-4484

    وصف الملف: application/pdf

    Relation: https://rsp.mediar-press.net/rsp/article/view/2732/1848; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с. [Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical recommendations. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p.].; Papagoras C, Voulgari PV, Drosos AA. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol. 2013;31:612-20. 3. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore). 2009;88:358-65. doi:10.1097/MD.0b013e3181c10773; Peters MJ, van Eijk IC, Smulders YM, et al. Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis. J Rheumatol. 2010;37:161-6. doi:10.3899/jrheum.090667; Heslinga SC, van den Oever IA, van Sijl AM, et al. Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation. BMC Musculoskelet Disord. 2015 Apr 9;16:80. doi:10.1186/s12891-015-0532-3; Eriksson JK, Jacobsson L, Bengtsson K, Askling J. Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis? Ann Rheum Dis. 2017 Feb;76(2):364-70. doi:10.1136/annrheumdis-2016-209315; Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011;70:1921-5. doi:10.1136/ard.2011.151191; Atzeni F, Dorea A, Nurmohamed M, Pauletto P. The Heart in Systemic Autoimmune Diseases. Handbook of Systemic Autoimmune Diseases. 2017. Vol. 14. ISBN: 978-0-12-803997-7; Haroon NN, Paterson JM, Li P, et al. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality. A population-based study. Ann Intern Med. 2015 Sep 15;163(6):409-16. doi:10.7326/M14-2470; Mathieu S, Gossec L, Dougados M, Soubrier M. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63:557-63. doi:10.1002/acr.20364; Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129-38. doi:10.1016/j.jacc.2009.09.009; Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol. 2007;100:32-40. doi:10.1016/j.amjcard.2007.08.011; Divecha H, Sattar N, Rumley A, et al. Cardiovascular risk parameters in men with ankylosing spondylitis in comparison with noninflammatory control subjects: relevance of systemic inflammation. Clin Sci (Lond). 2005;109:171-6. doi:10.1042/CS20040326; Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63:3294-304. doi:10.1002/art.30581; Maia DG, Augusto KL, Bezerra MC, Rodrigues CEM. Metabolic syndrome in patients with ankylosing spondylitis receiving anti-TNFα therapy: association with predictors of cardiovascular risk. Clin Rheumatol. 2017;36(10):2371-6. doi:10.1007/s10067-017-3623-8; Arida A, Protogerou AD, Konstantonis G, et al. Subclinical atherosclerosis is not accelerated in patients with ankylosing spondylitis with low disease activity: new data and metaanalysis of published studies. J Rheumatol. 2015;42(11):2098-105. doi:10.3899/jrheum.150316; Bodnar N, Kerekes G, Seres I, et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol. 2011;38(4):723-9. doi:10.3899/jrheum.100668; Yuan Y, Yang J, Zhang X, et al. Carotid Intima-Media Thickness in Patients with Ankylosing Spondylitis: A Systematic Review and Updated Meta-Analysis. J Atheroscler Thromb. 2018;25:000-000. doi:10.5551/jat.45294; Tam LS, Shang Q, Kun EW, et al. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis – a randomized, placebo-controlled pilot trial. Rheumatology (Oxford). 2014;53:1065-74. doi:10.1093/rheumatology/ket469; Van Eijk IC, Peters MJ, Serne EH, et al. Microvascular function is impaired in ankylosing spondylitis and improves after tumour necrosis factor alpha blockade. Ann Rheum Dis. 2009;68:362-6. doi:10.1136/ard.2007.086777; Van Sijl AM, van Eijk IC, Peters MJL, et al. Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis. Ann Rheum Dis. 2015;74:119-23. doi:10.1136/annrheumdis-2013-203934; Angel K, Provan SA, Gulseth HL, et al. Tumor necrosis factor-α antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension. 2010;55:333-8. doi:10.1161/HYPERTENSIONAHA.109.143982; Van der Heijde D, Ramiro S, Landewe R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91. doi:10.1136/annrheumdis-2016-210770; Mathieu S, Joly H, Baron G, et al. Trend towards increased arterial stiffness or intima-media thickness in ankylosing spondylitis patients without clinically evident cardiovascular disease. Rheumatology (Oxford). 2008;47:1203-7. doi:10.1093/rheumatology/ken198; Capkin E, Karkucak M, Kiris A, et al. Anti-TNF-alpha therapy may not improve arterial stiffness in patients with AS: a 24-week follow-up. Rheumatology (Oxford). 2012;51:910-4. doi:10.1093/rheumatology/ker434; Mathieu S, Pereira B, Couderc M, et al. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months. Rheumatology (Oxford). 2013;52:204-9. doi:10.1093/rheumatology/kes272; Кардиоваскулярная профилактика: национальные рекомендации. Кардиоваскулярная терапия и профилактика. 2011;10(Прил. 2):64 с. [Cardiovascular prevention: national guidelines. Cardiovascular therapy and prevention. 2011;10(Suppl. 2): 64 p. (In Russ).].; Kawasaki T, Sasayama S, Yagi S. Noninvаsive meаsurement of the age related changes in stiffness if major branches of the human arteries. Cardiovasc Res. 1987;144:345-52.; Парфeнов АС. Экспресс-диагностика сердечно-сосудистых заболеваний. Мир измерений. 2008;(6):74-82 [Parfenov AS. Express diagnostics of cardiovascular diseases. Mir Izmerenii. 2008;(6):74-82 (In Russ.)].; Гайдукова ИЗ, Ребров АП, Лапшина СА и др. Применение нестероидных противовоспалительных препаратов и генно-инженерных биологических препаратов для лечения аксиальных спондилоартритов. Рекомендации Экспертной группы по изучению спондилоартритов при Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2017;55(5):474-84 [Gaidukova IZ, Rebrov AP, Lapshina SA, et al. Use of nonsteroidal anti-inflammatory drugs and biological agents for the treatment of axial spondyloarthritides. Recommendations of the Spondyloarthritis Study Group of Experts, All-Russian Public Organization «The Association of Rheumatology of Russia». Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(5):474-84 (In Russ.)]. doi:10.14412/1995-4484-2017-474-484; Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4(4):CD005468. doi:10.1002/14651858.CD005468.pub2; Чичасова НВ. Значение иммуногенности при лечении ревматических заболеваний ингибиторами фактора некроза опухоли α. Современная ревматология. 2015;9(4):4-12 [Chichasova NV. Value of immunogenicity in the TNF-α inhibitor treatment of rheumatic diseases. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(4):4-12 (In Russ.)]. doi:10.14412/1996-7012-2015-4-4-12; Каратеев ДЕ. Факторы, определяющие длительный успех терапии генно-инженерными биологическими препаратами при ревматоидном артрите. Современная ревматология. 2015;9(3):54-60 [Karateev DE. Factors determining long-term success of biologic therapy in rheumatoid arthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(3):54-60 (In Russ.)]. doi:10.14412/1996-7012-2015-3-54-60; Inzinger M, Wippel-Slupetzky K, Weger W, et al. Survival and effectiveness of tumour necrosis factor-alpha inhibitors in the treatment of plaque psoriasis under daily life conditions: Report from the Psoriasis Registry Austria. Acta Derm Venereol. 2016;96:207-12. doi:10.2340/00015555-2214; Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008 Feb;117(2):244-79. doi: 10. 1016/j.pharmthera.2007.10.001; https://rsp.mediar-press.net/rsp/article/view/2732

  9. 9
    Conference

    المصدر: AIP Conference Proceedings ; PROCEEDINGS OF THE II INTERNATIONAL CONFERENCE ON ADVANCES IN MATERIALS, SYSTEMS AND TECHNOLOGIES: (CAMSTech-II 2021) ; volume 2467, page 020020 ; ISSN 0094-243X

  10. 10
    Academic Journal
  11. 11
    Academic Journal

    المصدر: Journal of Physics: Conference Series ; volume 798, page 012181 ; ISSN 1742-6588 1742-6596

    الاتاحة: http://dx.doi.org/10.1088/1742-6596/798/1/012181
    http://stacks.iop.org/1742-6596/798/i=1/a=012181/pdf
    http://stacks.iop.org/1742-6596/798/i=1/a=012181?key=crossref.e1911da5aa55fa77a7832ccbe189d3c5

  12. 12
    Academic Journal
  13. 13
    Academic Journal
  14. 14
    Academic Journal
  15. 15
    Academic Journal

    المصدر: Rheumatology Science and Practice; Vol 53, No 3 (2015); 258-265 ; Научно-практическая ревматология; Vol 53, No 3 (2015); 258-265 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20153

    وصف الملف: application/pdf

    Relation: https://rsp.mediar-press.net/rsp/article/view/2088/1314; Kaplan MJ. Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. Rheum Dis Clin North Am. 2010;36(2):405–26. doi:10.1016/j.rdc.2010.02.002; Avina-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta analysis of observational studies. Arthritis Rheum. 2008;59:1690–7. doi:10.1002/art.24092; Попкова ТВ, Новикова ДС, Насонов ЕЛ. Кардиоваскулярные факторы риска при ревматических заболеваниях: связь с воспалением. Consilium Medicum. 2010;(2):112–8. [Popkova TV, Novikova DS, Nasonov EL. Cardiovascular risk factors in rheumatic diseases: relationship with inflammation. Consilium Medicum. 2010;(2):112–8. (In Russ.)].; Кардиоваскулярная профилактика: национальные рекомендации. Кардиоваскулярная терапия и профилактика. 2011;10 приложение 2:64. [Cardiovascular prevention: national guidelines. Cardiovascular therapy and prevention. 2011;10, Suppl. 2:64 (In Russ.)].; Scarno A, Perrotta FM, Cardini F, et al. Beyond the joint: Subclinical atherosclerosis in rheumatoid arthritis. World J Orthop. 2014 July 18;5(3):328–35. doi:10.5312/wjo.v5.i3.328; Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8–26. [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): the role of methotrexate. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):8–26. (In Russ.)]. doi:10.14412/1995-4484-2014-8-26; Медведь ЕЭ, Дубиков АИ, Белоголовых ЛА. Влияние метотрексата и лефлуномида на цитокиновый профиль и метаболизм оксида азота у больных ревматоидным артритом. Научно-практическая ревматология. 2006;(4):58–62. [Medved' EJe, Dubikov AI, Belogolovyh LA. The ffect of methotrexate and Leflunomide on cytokine profile and metabolism of nitric oxide in patients with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2006;(4):58–62. (In Russ.)].; Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, ontrolled, phase IV trial. Arthritis Rheum. 2008;58(1):73–81. doi:10.1002/art.23144; Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно- практическая ревматология. 2013;51(2):117–25. [Karateev DE, Luchikhina EL, Muravyev YV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):117–25. (In Russ.)]. doi:10.14412/1995-4484-2013-637; Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008;21(2):93–111. doi:10.1016/j.echo.2007.11.011; Kawasaki T, Sasayama S, Yagi S. Noninvаsive meаsurement of the age related changes in stiffness if major branches of the human arteries. Cardiovasc Res. 1987;144:345–52.; Парфенов АС. Экспресс-диагностика сердечно-сосудистых заболевавний. Мир измерений. 2008;(6):74–82. [Parfenov AS. Express diagnostics of cardiovascular zabolevaniy. World measurements. 2008;(6):74–82. (In Russ.)].; Драпкина ОМ, Кабурова АН. Жесткость сосудов и диастолическая сердечная недостаточность. Терапевтический архив. 2013;(11):75–81. [Drapkina OM, Kaburova AN. Vascular stiffness and diastolic heart failure. Terapevticheskii arkhiv = Therapeutic Archives. 2013;(11):75–81. (In Russ.)].; Provan SA, Angel K, Semb AG, et al. Early prediction of increased arterial stiffness in patients with chronic inflammation: a 15-year followup study of 108 patients with rheumatoid arthritis. J Rheumatol. 2011;38:606–12 [PMID: 21239744]. doi:10.3899/ jrheum.100689; Ristic GG, Lepic T, Glisic B, et al. Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment. Rheumatology (Oxford). 2010;49:1076–81. [PMID: 20208070]. doi:10.1093/rheumatology/kep456; Van Sijl AM, Peters MJ, Knol DK, et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum. 2011;40:389–97. doi:10.1016/j.semarthrit.2010.06.006; Князева ЛА, Мещерина НС. Влияние терапии инфликсимабом на уровень иммунологических маркеров кардиоваскулярного риска и ремоделирование артериального русла у больных ревматоидным артритом. Курский научно-практический вестник «Человек и его здоровье». 2012;(4):49–55. [Knyazeva LA, Mescherina NS. Impact of infliximab treatment on the level of immunological markers of cardiovascular risk and arterial vasculature remodelling in patients with rheumatoid arthritis. Kurskiy scientificallypractical herald «Persons and his health». 2012;(4):49–55. (In Russ.)].; Попкова ТВ, Герасимова ЕВ, Новикова ДС, Насонов ЕЛ. Метотрексат и риск сердечно-сосудистых осложнений при ревматоидном артрите. Научно-практическая ревматология. 2012;50(6):70–9. [Popkova TV, Gerasimova EV, Novikova DS, Nasonov EL. Methotrexate and risk of cardiovascular events in rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(6):70–9. (In ss.)]. doi:10.14412/1995-4484-2012-1297; Wallberg-Jonsson S, Ohman M, Rantapа а-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? Scand J Rheumatol. 2004;33(6):373–9.; Kumeda Y, Inaba M, Goto H, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthr Rheum. 2002;46(6):1489–97. doi:10.1002/art.10269; Алиева АС, Ротарь ОП, Конради АО. Оценка субклинического поражения сосудов на популяционном уровне. Трансляционная медицина. 2014;(2):26–38. [Alieva AS, Rotar OP, Konradi AO. Subclinical vascular damage assessment on population level. Translyatsionnaya meditsina = Translational medicine. 2014;(2):26–38. (In Russ.)].; Гончаров ИС, Ахметов РЕ, Александрия ЛГ и др. Современные представления о роли артериальной ригидности в патогенезе сердечной недостаточности. Клиническая фармакология и терапия. 2013;22(3):53–60. [Goncharov IS, Akhmetov RE, Alexandriya LG, et al. Arterial stiffness and heart failure. Klinicheskaja farmakologija i terapija = Clinical pharmacology and therapeutics. 2013;22(3):53–60. (In Russ.)].; https://rsp.mediar-press.net/rsp/article/view/2088

  16. 16
    Academic Journal
  17. 17
    Periodical
  18. 18
  19. 19
  20. 20